Jazz Pharmaceuticals Cash Flow Statement
JAZZ / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Jazz Pharmaceuticals generated $1.4B in operating cash flow and $1.3B in free cash flow in FY2025. Free cash flow margin was 30.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | $238.6M | $487.8M | $396.8M | $487.8M | $58.4M | $329.5M | $288.6M | $216.3M | $288.6M | $125.0M |
| Depreciation & Amortization | $41.6M | $32.8M | $30.4M | $30.3M | $26.7M | $18.7M | $13.1M | $11.8M | $13.1M | $7.1M | $9.9M | $1.3M | - | $1.3M | - |
| Operating Cash Flow | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M | $899.6M | $693.1M | $592.4M | $693.1M | $407.6M | $531.9M | $249.8M | $288.4M | $249.8M | $151.6M |
| Capital Expenditures | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M | $15.0M | $28.9M | $9.7M | $28.9M | $36.3M | $36.0M | $6.0M | $10.0M | $6.0M | $1.3M |
| Free Cash Flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M | $884.6M | $664.1M | $582.7M | $664.1M | $371.3M | $496.0M | $243.8M | $278.5M | $243.8M | $150.3M |
| Share Buybacks | $125.0M | $311.4M | $269.8M | $54.0K | $0 | $146.5M | $98.8M | $278.3M | $98.8M | $42.2M | $61.6M | $0 | $136.5M | $0 | $0 |
| FCF Margin | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% | 37.4% | 41.0% | 39.2% | 176.6% | 31.6% | 37.4% | 41.6% | 31.9% | 41.6% | 55.2% |